Sansure Biotech Inc. (688289.SH): Relevant products have obtained the registration certificate of medical instruments.
On June 6th, Gelunhui announced that Sansure Biotech Inc. (stock code: 688289.SH) has recently received the Medical Device Registration Certificate issued by the National Medical Products Administration for its HBV RNA quantitative detection kit (PCR-fluorescent probe method) for hepatitis B virus. HBV RNA quantitative detection kit (PCR-fluorescent probe method) is the eighth kit registered by the company for medical devices in the field of screening and diagnosis of viral hepatitis. The detection sensitivity of the kit can reach 50copies/mL, and the linear range is 1.0E+02 copies.
Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing mor
Sansure Biotech Inc. (688289.SH) annual equity distribution in 2023: 2 yuan per 10 shares. Equity registration on June 7.
Sansure Biotech Inc. (688289.SH) issued the Annual Equity Distribution Implementation Notice for 2023, which will implement equity distribution...
Shengxiang Biotech (688289.SH) plans to establish a new joint venture with the Industrial Fund to focus on the field of rapid drug sensitivity testing
Shengxiang Biology (688289.SH) announced that the company intends to partner with the relevant party Hunan Xiangjiang Shengxiang Biological Industry Fund...
Shengxiang Biology (688289.SH): Plans to invest in Hunan Shengwei Sumin with related parties and transfer shares in the participating company FirstLight
On May 8, Ge Longhui Biotech (688289.SH) announced that it plans to jointly invest in the joint venture Hunan Shengwei Sumin Biotechnology Co., Ltd. (“Hunan Shengwei Sumin”) with the related party Hunan Xiangjiang Shengxiang Biological Industry Fund (limited partnership), of which the company's total investment amount is RMB 53.33 million. At the same time, the company plans to transfer 21.69% of the shares in the participating company FirstLightDiagnostics, Inc. (“FirstLight”) to a wholly-owned subsidiary of the joint venture with a consideration of 2,215,8
Sansure Biotech's (SHSE:688289) Earnings Quality Is Low
After announcing weak earnings, Sansure Biotech Inc.'s (SHSE:688289) stock was strong. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.
Sansure Biotech Inc.'s (SHSE:688289) Shares May Have Run Too Fast Too Soon
Sansure Biotech Inc.'s (SHSE:688289) price-to-sales (or "P/S") ratio of 10.8x might make it look like a strong sell right now compared to the Medical Equipment industry in China, where around half of
Shengxiang Biotech (688289.SH): Net profit of 81.025 million yuan in the first quarter increased 35.01% year-on-year
On April 26, Ge Longhui (688289.SH) released its report for the first quarter of 2024, achieving operating income of 391 million yuan, an increase of 100.31%; net profit attributable to shareholders of listed companies of 81.025 million yuan, an increase of 35.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 73.755 million yuan, an increase of 1962.06% year on year; basic earnings per share of 0.14 yuan.
Shengxiang Biotech (688289.SH) posted an advance increase. The net profit for the first quarter is expected to be 81.4891 million yuan, an increase of 35.79% over the previous year
Shengxiang Biotech (688289.SH) announced that the company expects to become a parent company in the first quarter of 2024...
Sansure Biotech (SHSE:688289) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Investors Will Want Sansure Biotech's (SHSE:688289) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expandi
Zhu Jinwei, shareholder of Shengxiang Biotech (688289.SH), reduced his holdings by 2% and the reduction period expired
Zhitong Finance App News, Shengxiang Biotech (688289.SH) issued an announcement. As of the disclosure date of this announcement, shareholder Zhu Jinwei had reduced his holdings of the company's shares by a total of 11.754,600 shares through centralized bidding transactions, accounting for 2% of the company's total shares. The time range for this holdings reduction plan has expired, and implementation has been completed.
Shengxiang Biotech (688289.SH): Net profit in 2023 fell 81.4% year on year
Gelonghui, Feb. 28, 丨 Shengxiang Biotech (688289.SH) announced its 2023 annual results report. Total operating revenue was RMB 1.06.4675 million, down 84.40% year on year, and net profit attributable to owners of the parent company was RMB 362.321 million, down 81.4% year on year. The company's total revenue and operating profit indicators for 2023 fell by more than 30% year-on-year, mainly due to changes in domestic and foreign public health prevention and control policies, which led to a sharp drop in demand for COVID-19 nucleic acid detection reagents and instruments, and a decline in related business revenue. Decrease in owners' equity vested in the parent company in 2023
Declining Stock and Decent Financials: Is The Market Wrong About Sansure Biotech Inc. (SHSE:688289)?
With its stock down 9.8% over the past month, it is easy to disregard Sansure Biotech (SHSE:688289). However, stock prices are usually driven by a company's financials over the long term, which in t
Shengxiang Biotech (688289.SH): The chairman and his co-actors plan to increase their shares by 50 million yuan to 100 million yuan
Gelonghui, Feb. 2: Shengxiang Biotech (688289.SH) announced that Mr. Dai Lizhong, the actual controller and chairman of the company, and his co-actors intend to increase the company's shares within 12 months from February 5, 2024 through methods permitted by the Shanghai Stock Exchange trading system (including but not limited to bidding transactions and bulk transactions, etc.), with a total increase of not less than 50 million yuan and no more than 10 million yuan.
Shengxiang Biotech (688289.SH): 2023 net profit pre-reduced by 80% to 82%
Gelonghui, January 22丨Shengxiang Biotech (688289.SH) announced its 2023 annual performance forecast. According to preliminary estimates by the finance department, the company expects to achieve operating income of 100,000 yuan to 102 million yuan in 2023. Compared with the same period last year, it will decrease 5430.36 million yuan to 5450.36 million yuan, a year-on-year decrease of 84.19% to 84.50%. Among them, the company achieved revenue of 632.54 million yuan in the first three quarters of 2023, and is expected to achieve operating income of 367.46 million yuan to 387.46 million yuan in the fourth quarter of 2023, an increase over the previous quarter
Shengxiang Biology (688289.SH) obtained a medical device registration certificate
Shengxiang Biology (688289.SH) issued an announcement. The company's product Coxsackie virus type A6/A10 nucleic acid test...
Shengxiang Biology (688289.SH): Novel coronavirus (2019-nCoV) nucleic acid test kit obtained medical device registration certificate
Gelonghui, December 27丨Shengxiang Biology (688289.SH) announced that the company's novel coronavirus (2019-nCoV) nucleic acid detection kit (fluorescence PCR method) recently received the “Medical Device Registration Certificate” issued by the State Drug Administration. This kit is used to qualitatively test in vitro throat swabs and nasopharyngeal swab samples of people with symptoms related to the novel coronavirus infection and others requiring diagnosis or differential diagnosis of the novel coronavirus infection. The test results of this kit should be combined with popularity
Shengxiang Biotech (688289.SH) grants 6.758,800 restricted shares at a price of 9.26 yuan/share
Shengxiang Biology (688289.SH) Notice, “Shengxiang Biotechnology Co., Ltd. 2023 Phase II Restrictions...
Following Recent Decline, Sansure Biotech Inc.'s (SHSE:688289) Top Shareholder CEO Lizhong Dai Sees Holdings Value Drop by 3.9%
Key Insights Insiders appear to have a vested interest in Sansure Biotech's growth, as seen by their sizeable ownership 51% of the business is held by the top 4 shareholders Institutional ownersh
No Data